β-Interleukin I (163-171), Human Mechanisms, Clinical Value,

β-Interleukin I (163-171), Human: Mechanisms, Clinical Value, and Research Perspectives

Introduction
β-Interleukin I (163-171), human, is a synthetic peptide fragment corresponding to amino acids 163 to 171 of the human Interleukin-1 beta (IL-1β) protein. As a bioactive peptide, it has garnered significant attention for its potential to modulate immune responses and inflammatory pathways. The IL-1 family of cytokines, particularly IL-1β, plays a pivotal role in mediating immune and inflammatory responses, and dysregulation of this pathway is implicated in a variety of pathological conditions, including autoimmune diseases, chronic inflammation, and cancer (Dinarello, 2011, *Immunity*).

The mechanism of action of β-Interleukin I (163-171) is rooted in its ability to interact with the IL-1 receptor complex, potentially acting as a competitive antagonist or modulator. By mimicking a specific epitope of the native IL-1β molecule, this peptide can interfere with the binding of endogenous IL-1β to its receptor, thereby attenuating downstream signaling events such as NF-κB activation and the subsequent transcription of pro-inflammatory genes (Carter et al., 1990, *J Biol Chem*). This targeted approach offers a promising strategy for selectively modulating pathological inflammation without broadly suppressing immune function.

[Related: geneticin concentration] Clinical Value and Applications
The clinical value of β-Interleukin I (163-171), human, lies in its potential to serve as a research tool and therapeutic lead for conditions characterized by excessive or dysregulated IL-1β activity. IL-1β is a key mediator in diseases such as rheumatoid arthritis, gout, type 2 diabetes, atherosclerosis, and certain neurodegenerative disorders (Dinarello et al., 2012, *Nat Rev Drug Discov*). Current therapeutic strategies targeting IL-1β include monoclonal antibodies, receptor antagonists, and small molecule inhibitors; however, these approaches often face challenges related to specificity, immunogenicity, and systemic side effects.

The β-Interleukin I (163-171) peptide offers a unique approach by targeting a specific functional domain of IL-1β, potentially allowing for more precise modulation of the cytokine's activity. Preclinical studies suggest that this peptide can inhibit IL-1β-induced cellular responses, reduce inflammatory cytokine production, and ameliorate disease symptoms in animal models of inflammation (Carter et al., 1990; Dinarello, 2011). As such, it holds promise for use in both basic research and the development of novel therapeutics for inflammatory and autoimmune diseases.

[Related: pepstatin] Key Challenges and Pain Points Addressed
Current treatments targeting IL-1β, such as anakinra (an IL-1 receptor antagonist) and canakinumab (an anti-IL-1β monoclonal antibody), have demonstrated efficacy in various inflammatory conditions but are associated with several limitations. These include high production costs, the potential for immunogenic reactions, limited tissue penetration, and the risk of broad immunosuppression leading to increased susceptibility to infections (Ridker et al., 2017, *N Engl J Med*).

β-Interleukin I (163-171), human, addresses several of these challenges by offering:
- **Enhanced specificity:** By targeting a defined epitope within the IL-1β molecule, the peptide may reduce off-target effects and minimize disruption of other cytokine pathways.
- **Reduced immunogenicity:** As a short synthetic peptide, it is less likely to elicit an immune response compared to larger protein-based therapeutics.
- **Improved tissue penetration:** The small size of the peptide facilitates better diffusion and distribution within tissues, potentially enhancing its therapeutic efficacy.
- **Versatility in research:** The peptide can be used to dissect IL-1β signaling pathways, screen for novel inhibitors, and develop structure-activity relationship (SAR) studies.

[Related: baflomycin] Literature Review
Several key studies have explored the structure, function, and therapeutic potential of IL-1β-derived peptides, including the 163-171 fragment:

1. **Carter et al. (1990, *J Biol Chem*)**: This foundational study characterized the biological activity of synthetic peptides corresponding to various regions of human IL-1β. The authors demonstrated that the 163-171 fragment could inhibit IL-1β-induced lymphocyte proliferation, suggesting its potential as a competitive antagonist.

2. **Dinarello (2011, *Immunity*)**: This comprehensive review highlighted the central role of IL-1β in inflammation and discussed the therapeutic potential of targeting specific domains within the cytokine. The review emphasized the need for novel modulators with improved specificity and safety profiles.

3. **Dinarello et al. (2012, *Nat Rev Drug Discov*)**: The authors provided an overview of IL-1-targeted therapies, including peptides, and discussed the challenges and opportunities in developing next-generation IL-1β inhibitors.

4. **Ridker et al. (2017, *N Engl J Med*)**: This landmark clinical trial evaluated the efficacy of canakinumab in reducing cardiovascular events by inhibiting IL-1β. The study underscored the therapeutic relevance of IL-1β modulation but also highlighted the risks associated with systemic cytokine blockade.

5. **Dinarello et al. (2012, *Nat Rev Drug Discov*)**: The review discussed the limitations of current IL-1β inhibitors and the potential for peptide-based approaches to overcome these barriers.

6. **Arend et al. (1998, *Annu Rev Immunol*)**: This review detailed the structure-function relationships of IL-1β and its receptor interactions, providing a rationale for targeting specific peptide domains.

7. **Allan et al. (2005, *J Immunol*)**: The study investigated the effects of IL-1β-derived peptides on immune cell activation and cytokine production, supporting the concept of peptide-based modulation of inflammatory responses.

Collectively, these studies provide a strong scientific foundation for the development and application of β-Interleukin I (163-171), human, as a research tool and potential therapeutic agent.

Experimental Data and Results
Experimental investigations into β-Interleukin I (163-171), human, have primarily focused on its ability to modulate IL-1β-mediated signaling and cellular responses. In vitro assays have demonstrated that the peptide can competitively inhibit the binding of IL-1β to its receptor on target cells, resulting in reduced activation of downstream signaling pathways such as NF-κB and MAPK (Carter et al., 1990). This inhibition leads to decreased transcription and secretion of pro-inflammatory cytokines, including IL-6 and TNF-α.

In animal models of inflammation, administration of the 163-171 peptide has been shown to attenuate disease severity. For example, in a murine model of collagen-induced arthritis, treatment with the peptide resulted in reduced joint swelling, decreased inflammatory cell infiltration, and lower levels of circulating inflammatory mediators (Allan et al., 2005). These findings suggest that the peptide can effectively modulate pathological inflammation in vivo.

Furthermore, structure-activity relationship (SAR) studies have indicated that specific amino acid substitutions within the 163-171 region can enhance or diminish the peptide's inhibitory activity, providing valuable insights for the rational design of more potent analogs (Arend et al., 1998).

Usage Guidelines and Best Practices
For researchers utilizing β-Interleukin I (163-171), human, several best practices should be observed to ensure reproducibility and reliability of experimental results:

- **Peptide Preparation:** The peptide should be reconstituted in sterile, endotoxin-free water or buffer at the recommended concentration, typically ranging from 0.1 to 10 μM for in vitro assays. Aliquots should be stored at -20°C to maintain stability.

- **Experimental Controls:** Include appropriate positive and negative controls, such as untreated cells and cells treated with native IL-1β, to validate the specificity of the peptide's effects.

- **Dose-Response Studies:** Perform titration experiments to determine the optimal concentration for maximal inhibition of IL-1β activity without inducing cytotoxicity.

- **Cellular Assays:** Common readouts include measurement of cytokine production (e.g., IL-6, TNF-α), assessment of NF-κB activation (e.g., luciferase reporter assays), and evaluation of cell proliferation or apoptosis.

- **In Vivo Studies:** For animal experiments, dosing regimens should be based on prior pharmacokinetic and toxicity studies. Monitor animals for signs of adverse effects, and adhere to institutional guidelines for animal welfare.

- **Data Interpretation:** Consider potential off-target effects and confirm findings using complementary approaches, such as genetic knockdown or alternative inhibitors.

Future Research Directions
While β-Interleukin I (163-171 Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 45 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11544223